Business
CDT is a clinical-stage company seeking to reposition and develop pharmaceutical compounds, including AZD1656 cocrystal assets and related drug candidates.
CDT is a clinical-stage asset-repositioning company with no revenue row, a larger loss, negative FCF, and repeated filing-control events.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage drug assetsNote
- Revenue — N/ANote
- Operating loss — ($36.8M), widerWatch
- Net loss — ($39.2M), widerWatch
- FCF — ($15.6M)Watch
- Equity — ($7.2M), deficitWatch
- Insiders — 0 purchases and 0 salesNote
Leadership changes
From CDT Equity Inc.'s own filings, the day they're filed.
- James Bligh · Chief Financial Officer · appointmenteff. 2025-08-04
- Andrew Regan · Chief Executive Officer · appointmenteff. 2025-04-15
- Simon Fry · director · appointmenteff. 2024-12-18
Latest filings
- 8-K · Company announcement2026-09-01
- 8-K · Company announcement2026-09-01
- 10-Q · Quarterly report2026-08-12
- DEF 14A · Annual proxy (pay & governance)2026-08-11
- 8-K · Company announcement2026-08-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CDT Equity Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.